Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure
Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the response rate at 6 months in Myelodysplastic
Syndrome (MDS) patients, Chronic Myelomonocytic Leukaemia (CMML-2) patients, and Acute
Myeloid Leukaemia (AML) patients with up to 30% bone marrow blasts, treated with low-dose
decitabine who have previously failed therapy with 5-azacitidine.